Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Inspiratory Muscle Training Plus Cold Water Immersion After Muscle-Damaging Exercise

3 de noviembre de 2026 actualizado por: Mete Berk Demiryol, University of Gaziantep

The Combined Effect of Cold Water Immersion and Inspiratory Muscle Training on the Recovery From Exercise-Induced Muscle Damage and Physical Performance: A Randomized, Placebo-Controlled Crossover Study

The purpose of this study is to examine, using a placebo-controlled design, the additional effect of inspiratory muscle training (IMT) added to cold water immersion (CWI) on recovery and muscle performance following exercise-induced muscle damage (EIMD), and to determine whether this effect varies depending on the timing of the intervention. The study will include 12 healthy male athletes aged 18-22 who have been licensed for at least 4 years and are actively involved in sports. Each participant will undergo four different interventions in a randomized order determined by the Williams balanced sequence following muscle damage induced by eccentric exercise on an isokinetic dynamometer: CWI + placebo IMT immediately after exercise, IMT + CWI immediately after exercise, IMT + CWI 24 hours after exercise, and a control condition with no recovery intervention. The sessions will be conducted in weekly cycles with 7-day intervals, alternating between the dominant and non-dominant legs; thus, there will be a 14-day interval between two loading sessions for the same leg. All measurements will be taken during the week. Muscle strength will be assessed using an isokinetic dynamometer; markers of muscle damage (CK, myoglobin, LDH) will be measured via blood samples; and muscle pain will be evaluated using the Visual Analog Scale (VAS) before each exercise session and 48 hours after exercise.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

12

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Şehitkamil
      • Gaziantep, Şehitkamil, Turquía (Türkiye)
        • Gaziantep University, Faculty of Sports Sciences, Sports Performance and Testing Laboratory

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 22 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  • Be a male between the ages of 18 and 22
  • Hold a sports license valid for at least 4 years
  • Be actively involved in sports
  • Not smoke or use similar substances

Exclusion Criteria:

  • Having sustained a sports injury within the past 2 years
  • Having engaged in exercise that could cause muscle damage within the past 15 days
  • Cold intolerance, cold urticaria, or Raynaud's phenomenon
  • Known cardiovascular, respiratory, or musculoskeletal disease
  • Use of anti-inflammatory medication or dietary supplements that could affect recovery during the study period

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador falso: CWI + placebo IMT

Device: Placebo IMT - 2 × 30 breaths at 15% of MIP using POWERbreathe (1 min between sets), immediately following the short test after EIMD. Other: Immersion in cold water - immediately following the placebo IMT, in 10-12 °C water, up to waist level or with legs fully submerged, for 10-15 minutes.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Same device, position and volume as inspiratory muscle training (two sets of 30 breaths, 1 minute rest), but at 15% of maximal inspiratory pressure, a load considered below the training threshold. Followed immediately by cold water immersion.

Experimental: IMT + CWI (immediately)

Other: Inspiratory muscle training + cold water immersion. Immediately following the short test after EIMD, 2 × 30 breaths at 40% of MIP using POWERbreathe (1 min rest between sets), followed by CWI.

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Experimental: IMT + CWI (at 24 hours)

Other: Inspiratory muscle training + cold water immersion. The same IMT and CWI protocol is administered 24 hours after EIMD; the 48-hour measurement is taken relative to EIMD (24 hours after the intervention).

Immersion up to the waist in water at 13-15 °C for 13-15 minutes in a portable ice bath; water temperature is monitored with a thermometer and maintained by adding ice.

Two sets of 30 breaths at 40% of maximal inspiratory pressure with 1 minute rest between sets, using a POWERbreathe device; oxygen saturation is monitored by pulse oximetry. Followed immediately by cold water immersion.

Sin intervención: Control

No recovery procedure is performed after the EIMD protocol; only measurements are taken.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Peak Power ( 60°/s)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 5-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Peak Power ( 180°/s)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Highest torque (Nm) measured during a 10-rep maximum test on an isokinetic dynamometer

The 48-hour period before and after EIMD in each phase
Average Power ( 180°/s- 60°/s)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Average of peak torque values during test repetitions (Nm)

The 48-hour period before and after EIMD in each phase
Serum creatine kinase (CK)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

CK level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase
Myoglobin (Mb)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Myoglobin level in venous blood (ng/mL)

The 48-hour period before and after EIMD in each phase
Lactate dehydrogenase (LDH)
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

LDH level in venous blood (U/L)

The 48-hour period before and after EIMD in each phase

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
H/Q ratio
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Hamstring-to-quadriceps peak torque ratio (60°/s and 180°/s)

The 48-hour period before and after EIMD in each phase
VAS
Periodo de tiempo: During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD

0-10 cm Visual Analog Scale (0 = no pain, 10 = very severe pain)

During each period: before EIMD, immediately after EIMD, and 48 hours after EIMD
Fatique Index
Periodo de tiempo: The 48-hour period before and after EIMD in each phase

Fatigue index (%) calculated from a test consisting of 10 cycles at 180°/s

The 48-hour period before and after EIMD in each phase

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2026

Finalización del estudio (Estimado)

31 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

27 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2026/9504

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

"Individual participant data will not be shared for privacy reasons; aggregate results will be published."

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir